Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Mar 2021 · 1 min read
In brief
In brief
This preclinical study demonstrates that EYA3, a protein upregulated by the EWSR1/FLI1 fusion in Ewing sarcoma, promotes tumor growth through VEGFA-mediated angiogenesis and DNA damage repair. Both genetic knockout and pharmacologic inhibition with Benzarone reduced tumor growth in xenograft models, validating EYA3 tyrosine phosphatase as a potential therapeutic target.
Written by the GCMD Library team from the article.
Statements in this article
EWSR1/FLI1, the most common fusion gene in Ewing sarcoma, upregulates expression of the Eyes Absent 3 (EYA3) transactivator-phosphatase protein.
Loss of EYA3 in Ewing sarcoma cells inhibits tumor growth and tumor angiogenesis.
Pharmacologic inhibition of the EYA3 tyrosine phosphatase activity inhibits tumor growth and tumor angiogenesis.
EYA3 regulates levels of VEGFA in Ewing tumors.
EYA3 promotes DNA damage repair and survival of Ewing sarcoma tumor cells.
Target engagement is demonstrated in tumor tissue through elevated levels of the EYA3 substrate H2AX-pY142 upon loss of EYA3 or with Benzarone treatment.
The efficacy of EYA3 tyrosine phosphatase inhibition in attenuating tumor growth and angiogenesis is corroborated in an Ewing sarcoma patient-derived tumor xenograft.